Pfizer’s Paxlovid Likely Relegated To High-Risk COVID-19 Patients
The company announced updated results from a standard-risk study, which it will include in its overall new drug application, but whether Paxlovid will see approval or uptake in that group is another question.
You may also be interested in...
AstraZeneca also published efficacy data for Evusheld in patients with mild-to-moderate COVID-19, while Pfizer is investing $120m in expanding its Paxlovid manufacturing footprint in Michigan.
A Phase II/III trial testing Paxlovid as a preventative treatment for COVID-19 failed to show a statistically significant efficacy benefit.
The US FDA’s Christmas gift was the authorization of the first oral pill for treatment of mild-to-moderate COVID-19; Pfizer expects to have 30 million doses of Paxlovid available by mid-2022.